Potentially inactivating mutations in components of the RhoA pathway, including RhoA itself and the RhoA-GEF ARHGEF1, have also been reported in two B cell lymphomas, Burkitt’s lymphoma (BL) and GC B-cell-derived diffuse large B cell lymphoma (DLBCL)33,55,56. The gene discussed is RHOA; the disease is B-cell non-Hodgkin lymphoma.